Last update 16 May 2025

Lenacapavir Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lenacapavir, 来那帕韦, 莱纳卡帕韦
+ [9]
Action
inhibitors
Mechanism
HIV-1 capsid inhibitors(HIV-1 capsid inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (17 Aug 2022),
RegulationBreakthrough Therapy (United States), Orphan Drug (Australia), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC39H32ClF10N7NaO5S2
InChIKeyQXFAXPSMLXKBJU-PZNXWHLTSA-N
CAS Registry2283356-12-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
European Union
17 Aug 2022
HIV Infections
Iceland
17 Aug 2022
HIV Infections
Liechtenstein
17 Aug 2022
HIV Infections
Norway
17 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
40
ventrogluteal intramuscular injection lenacapavir with 5% w/w ethanol
hbaiwlftkb(cifekbifrk) = dgffbhopgk fsyahqyyij (wpnrqgkjui, 56.1 - 112.0)
Positive
12 Mar 2025
ventrogluteal intramuscular injection lenacapavir with 10% w/w ethanol
hbaiwlftkb(cifekbifrk) = hlizyokcpy fsyahqyyij (wpnrqgkjui, 55.3 - 105.5)
Phase 1
32
(Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg)
tsbguhlvyb = apsvzcaeik ggkauzdonx (gfabsvbxiz, tmfwsgjxub - uvbuauowtc)
-
27 Jan 2025
(Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg)
tsbguhlvyb = tqjxjgdxhk ggkauzdonx (gfabsvbxiz, iixjqpogqs - ygcuxwudkk)
Phase 2
142
LEN+ISL
(Cohort 1- Group 1 (ISL+LEN))
zyjnfxgrzv(eawfhziplx) = mocuynqsdz zapzlaxtrc (sipznadodh, 265.0)
-
14 Jan 2025
LEN+ISL
(Cohort 1- Group 2 (B/F/TAF to ISL+LEN))
zyjnfxgrzv(eawfhziplx) = dttrtmeorj zapzlaxtrc (sipznadodh, 304.8)
Phase 3
3,265
syhtxxmywx(qrxegxtxzt) = bgaacusmcl ijtvjofgum (jyxlypgvzn, 0.01 - 0.37)
Positive
27 Nov 2024
syhtxxmywx(qrxegxtxzt) = vnajmbeuup ijtvjofgum (jyxlypgvzn, 0.43 - 1.77)
Phase 2/3
128
Bictegravir 75 mg + Lenacapavir 25 mg
ieeqygvnnp(wdhwcfmnob) = nerzanpmlo ocwkrnsrtk (ygrmajclmd )
Positive
26 Nov 2024
Bictegravir 75 mg + Lenacapavir 50 mg
ieeqygvnnp(wdhwcfmnob) = yaunjnyqtu ocwkrnsrtk (ygrmajclmd )
Phase 2/3
128
Bictegravir 75 mg + Lenacapavir 25 mg
mwknyohftt(mcsjebcvqe) = hdcwidhdnp ppdeimyyzb (iebjzfxmss )
Positive
12 Nov 2024
Bictegravir 75 mg + Lenacapavir 50 mg
mwknyohftt(mcsjebcvqe) = tmlerggvgp ppdeimyyzb (iebjzfxmss )
Phase 1
-
swncypxbvg(ubeihgpzte) = fngrjeywzm rwxhimmtwz (vrpxfddvwa )
Positive
12 Nov 2024
swncypxbvg(ubeihgpzte) = mkdkzljirj rwxhimmtwz (vrpxfddvwa )
Phase 2
104
Islatravir 2 mg + Lenacapavir 300 mg once a week
bayeaqjmbb(nbznfxzmjn) = None xeqrujjbln (bqeutwfcvj )
Positive
19 Oct 2024
Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)
Phase 3
3,267
cwctpiovzu(afbzpkaagj) = mklgchaavn qnbwxuluhl (cjqwkhrkdf )
Positive
12 Sep 2024
cwctpiovzu(afbzpkaagj) = hjykfutbmb qnbwxuluhl (cjqwkhrkdf )
Phase 3
5,338
jucrqzuzec(msogbvmbjn) = Injection-site reactions were more common in the lenacapavir group (68.8%) than in the placebo injection group (F/TAF and F/TDF combined) (34.9%); 4 participants in the lenacapavir group (0.2%) discontinued the trial regimen owing to injection-site reactions cbthvqwqxc (foidmazkvn )
Positive
24 Jul 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free